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Condensed abstract 
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Disease of the proximal left anterior descending artery (LAD) is a common 
pathological finding often combined with disease in other coronary arteries. In 
this article we review specifically the evidence (and the guidelines arising from 
the data) for lesions isolated to the proximal LAD only. Critical review of the data 
reveals limitations with few trials that reflect contemporary practice. Much of the 
data is observational rather than from randomised trials and therefore subject to 
bias. We identified two randomised trials of drug-eluting stents versus LIMA for 
isolated lesions of the proximal LAD. One reported no difference in MACE but at 
an early time-point (6-months), which is likely to be too early to reveal treatment 
differences. In the second trial TLR excess was noted in the drug-eluting stent 
arm. Therefore at the current time little data is available to inform interventional 
cardiologists as to the best revascularisation strategy for isolated lesions of the 
proximal LAD. Further randomised control trials are urgently needed. 
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Disease of the proximal left anterior descending artery (LAD) is a common 
pathological finding often combined with disease in other coronary arteries. In 
this article we review specifically the evidence (and the guidelines arsing from the 
data) for lesions isolated to the proximal LAD only.  
 
Methods 
The primary aim was to perform a systematic review of the published data 
comparing coronary artery bypass grafting (CABG) versus percutaneous coronary 
intervention (PCI) for isolated stenoses of the proximal LAD. Using Medline and 
Google Scholar the search was limited to studies published in English between 
1998 and 2014. Search keywords included (“Minimally invasive direct coronary 
artery bypass” OR “MIDCAB” OR ‘Coronary Artery Bypass’) AND (‘Percutaneous 
Coronary Intervention’ OR PCI OR primary stenting OR stenting) AND (Left 
Anterior Descending). To broaden the search we also crosschecked the references 
of the articles identified in the initial Medline results as well the references of the 
several published meta-analyses. Finally the references of the major guidelines 
discussed were also searched. Eleven studies were identified that compared bare-
metal stent PCI or balloon angioplasty (PCI-BMS) versus CABG and 9 studies that 
compared drug-eluting stent PCI (PCI-DES) versus CABG. Several observational 
studies were identified that compared mixed BMS and DES use against CABG and 
these were excluded. 
 
Bare Metal Stents vs. CABG 
Underpinning both the European guidelines and the US guidelines for 
revascularisation of the isolated proximal LAD stenoses are two large meta-
analyses examining the outcomes of a series of historical trials comparing CABG 
vs. PCI (almost exclusively with BMS) for isolated proximal LAD disease: 1) Aziz 
et al who performed a meta-analysis of minimally invasive internal thoracic artery 
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bypass versus percutaneous revascularisation for isolated lesions of the LAD in 
>1900 patients; 2) Kapoor et al who examined outcomes of isolated disease of 
the proximal LAD comparing the effectiveness of percutaneous coronary 
interventions and CABG surgery in >1200 patients.1-5 Although there were no 
differences in either meta-analysis for mortality, myocardial infarction (MI) or 
stroke between the two revascularisation strategies there was a three to five fold 
increase in repeat target vessel revascularisation (TVR) in patients treated with 
PCI compared to CABG.  
 
Although at first glance this evidence appears impressive (21 studies reporting 
outcomes of 3,162 patients) it is important to note is that the two meta-analyses 
largely reproduce the same studies and duplicate the patient numbers. After 
exclusion of duplicated studies the 2 meta-analyses report the findings of 11 
studies of 2380 patients. The 11 studies reported in total are summarised in 
Table 1.6-16 Additionally the two largest studies were non-randomised 
observational studies that may duplicate the same group of patients.11,13 Given 
the limitations of such observational data in these 2 studies the meta-analyses 
authors actually excluded  them from their main analysis. Also it is important to 
note however that the largest of randomised study of PCI-BMS vs. CABG included 
only 220 patients.12 
 
Therefore the meta-analyses finally report 9 studies report the outcomes of 1239 
patients randomised to PCI or CABG providing the best quality data with selection 
and treatment biases are minimised as far a possible. In analysing the 
randomised subgroup Kapoor et al found that although there were no differences 
in survival, strokes or myocardial infarctions at 30 days, 1 year, or 5 years, 
repeat revascularization was significantly less after CABG than after PCI (at 1 
year: 7.3% vs. 19.5%; at 5 years: 7.3% vs. 33.5%). Additionally angina relief 
was significantly greater after CABG than after PCI (at 1 year: 95.5% vs. 84.6%; 
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at 5 years: 84.2% vs. 75.6%). Similarly in an analysis confined to the 
randomised trials only Aziz et al found no differences in death, MI or stroke but 
showed a higher rate of recurrence of angina (odds ratio 2.62, 95% confidence 
interval 1.32 to 5.21) and need for repeat revascularisation (4.63, confidence 
interval 2.52 to 8.51) with percutaneous stenting. Therefore within their 
acknowledged limitations these 2 meta-analyses appear to demonstrate the 
superiority of CABG over PCI for the revascularisation of proximal LAD stenosis 
with respect to symptom relief and repeat revascularization, but not for death, 
stroke or MI. However it is important to note that several of these studies had 
short follow up (<12-months) and more prolonged follow-up may have further 
emphasized the superiority of CAGB over PCI. Although hard clinical end-points 
such as repeat revascularisation occur less frequently with CABG than PCI-BMS it 
is interesting to note that in the two studies that reported on quality of life (as 
measured by Seattle Angina Questionnaire (SAQ) and the Medical Outcomes 
Study 36-Item Short Form Health Survey (SF-36)) there was little difference 
between the two treatments. 8,14 However there was a significant improvement in 
quality of life with both treatments at follow-up compared to baseline and such 
outcome data is very relevant when informing patient choice prior to treatment. 
 
The SIMA trial recently reported the 10 year follow up of the original cohort 
reported in 1998 (and included in the meta-analyses).7,36 In this report a decade 
on, not one patient with a LIMA to the LAD had undergone repeat 
revascularisation to the LAD compared to 16 (25.8%) patients who received a 
bare metal stent. Interestingly the non-LAD revascularisation rates were identical 
and very low (4.8% vs. 4.8%) in the two study arms. This long follow up and lack 
of need for revascularisation in the CABG arm reinforce the excellent outcomes of 
a LIMA to the LAD. It is an impressive benchmark against which PCI (DES or not) 
must perform. 
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Relevance to contemporary clinical practice 
One consideration in assessing the strength of these data is the comparison of 
practice between the included studies and contemporary PCI practice. Kapoor et 
al published their paper in 2008 and included trials that recruited patients 
between 1989 and 2003. Similarly Azziz et al published their analysis in 2007 and 
included trials that recruited patients between 1998 and 2003. As a result only 
one trial in these meta-analyses used drug-eluting stents (PCI-DES) with CABG. 
Additionally three of the randomised studies did not involve routine bare metal 
stent (PCI-BMS) use and either were solely balloon angioplasty without stenting 
or a mixture of balloon angioplasty only and/or stents.6,9,14 In current PCI practice 
stents are standard of care and it would be extremely unusual to perform balloon 
angioplasty only (without stenting) of the proximal LAD artery. Additionally in 
contemporary practice drug-eluting stents rather than a bare-metal stent would 
commonly be used in the proximal LAD. However only one study included in 
either meta-analysis utilised drug-eluting stents (Hong et al) randomising 119 
patients to a first generation Cypher stent or 70 patients to CABG (see below).  
 
Whilst the data supporting the conclusion that PCI-BMS increase the risk of TVR 
three to five-fold compared to CABG appears robust, it is important to note that 
these remaining studies do not show any evidence of a mortality benefit with 
CABG vs. PCI-BMS with the benefit of CABG being exclusively driven by TLR. Two 
other meta-analyses of the same trials have largely reproduced the findings of 
the two meta-analyses reported in the 2010 guidelines.17,18 What does appear 
clear however from later large scale randomised control trials and subsequent 
meta-analyses is that drug-eluting stents offer a significant reduction in TLR when 
compared to bare metal stents. Indeed several meta-analyses of RCTs comparing 
first generation DES with BMS report similar rates of death, cardiac death, and 
non-fatal myocardial infarction, but a 50-70% relative risk reduction in repeat 
target vessel revascularization with DES.19  
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Drug-eluting stents vs. CABG 
In an attempt to derive further insights into comparisons between PCI-DES and 
CABG (and thus to draw conclusions regarding contemporary practice) we 
identified 9 studies of 2752 patients comparing PCI-DES with CABG for isolated 
LAD stenosis and these are listed in Table 2.20-29 However as with the PCI-BMS 
vs. CABG data the majority of the studies are observational and retrospective in 
design. Only 2 studies were randomised with a total of 184 patients treated by 
PCI-DES and 135 by CABG.20,24 Therefore there are very limited data from which 
conclusions can to drawn as to the optimal revascularisation strategy for isolated 
proximal LAD disease in contemporary practice. Additionally the findings from the 
two studies rather than being consistent are divergent. Hong et al found no 
difference in TLR between the PCI-DES and CABG cohorts but the very short 
follow-up (6-months) is a limitation and reduces the robustness of the conclusion 
that the two strategies offered comparable TLR rates.20 In contrast at 12-months 
Thiele et al reported a 6.2% TLR rate in the PCI-DES group vs. 0% in the CABG 
group, a finding which indicated a failure of a non-inferiority comparison between 
PCI-DES and CABG.24 At 7-year follow-up the authors reported similar death and 
MI rates between the two revascularisation strategies but a very significant 
excess of TLR in the PCI-DES cohort (20.0% vs. 1.5%) that was highly 
statistically significant.25 Although only a single study has reported on the quality 
of life with PCI-DES vs. CABG, as with studies comparing PCI-BMS with CABG 
there appears to be little difference in quality of life between treatments as 
measured by SF-36 at either 12-months or 7-years follow-up.24,25 
 
In examining the results of the retrospective observational analyses of PCI-DES 
vs. CABG it is also unexpected to observe that the results favour CABG (Table 2). 
In the absence of definitive data many interventionalists in practice are likely to 
undertake PCI in “straightforward” lesions and refer complex unsuitable lesions 
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for CABG. Therefore one might expect that PCI would perform well in these 
circumstances vs. CABG but the data as it is do not support this hypothesis. The 
confounding effect of baseline factors such as age and comorbidity is uncertain 
and as yet unstudied. The optimal strategy in contemporary practice needs to be 
properly tested in an appropriately powered randomized trial to be definitive and 
powered to allow age and comorbidity to be sufficiently stratified.  
 
Two meta-analyses including the randomised and observational studies for DES-
PCI vs. CABG have been performed.30,31 In the first a subgroup analysis 
concluding that the PCI-DES cohort (4 studies; 456 patients) had a higher risk of 
recurrent angina (risk ratio 3.4, 95% CI: 1.9 to 6.2; p < 0.001) and target vessel 
re-interventions (risk ratio 4.16, 95% CI: 2.7 to 6.6; p < 0.001) at midterm 
follow-up (2-5 years).30 The second meta-analysis considered only the 
randomised trials of PCI-DES vs. CABG for proximal LAD disease as part of a 
larger meta-analysis of stents vs. CABG but reported that the data was 
insufficient for any firm conclusions to be made.31 Aside from the relative lack of 
data (randomised or not) and the divergent results it must be recognized that 
both randomized trials and the majority of the observational trial used first 
generation stents (Cypher or Taxus). Studies of newer generation DES (such as 
Xience or Resolute) however report a 35% reduction of mortality, 30% reduction 
in cardiac death and myocardial infarction and >50% reduction in stent 
thrombosis at >3 years follow up compared to first generation DES.32,33 However 
whether this observed TLR reduction in stent vs. stent trials translates into 
equivalency against CABG (or indeed superiority) for revascularisation of an 
isolated proximal LAD stenosis whilst seeming intuitively plausible remains 
unproven. 
 
Most recently Hannan et al propensity matched 715 pairs of patients who were 
treated with either DES or CABG for isolated LAD stenoses between 2008 and 
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2010 using a United States registry.34 Mortality, MI and stroke were similar at 3-
year follow-up between DES and CABG but despite the apparent contemporary 
practice repeat revascularisation rates were almost twice as high with DES (12.98 
vs. 7.09%). Therefore even the most contemporary data (albeit registry-derived) 
appears to support CABG as the optimal revascularisation strategy for isolated 
proximal LAD disease. 
 
The premise that proximal LAD lesions place patients at particular risk and thus 
deserves particular focus derives from the large territory of myocardium 
subtended, and hence at risk from vessel restenosis/occlusion. The left main stem 
subtends an even greater territory, so the recently published 5-year data from 
the SYNTAX trial on this sub-group is of some reassurance to interventionalists in 
the current proximal LAD data void.35 Although it is tempting to extrapolate the 
SYNTAX left main data to support a PCI revascularisation strategy for proximal 
coronary lesions it is important to remember that the left main stem is 
significantly larger in diameter and shorter in length than the LAD, both factors 
which could impact on long term outcomes with stents. From a scientific 
perspective this “leap of faith” remains speculative at best because as noted 
above there are no published trials (first or second generation DES) that shows 
equivalency of PCI to CABG beyond 12-months of follow-up. Additionally given 
the lack of contemporary trial data the impact of improved surgical techniques 
during CABG and increased utilisation of off-pump surgery on the outcomes vs. 
PCI is also uncertain. 
 
Revascularisation guidelines 
In 2010 the European Society of Cardiology published revascularisation guidelines 
recommending CABG as being preferable to PCI in patients with proximal left 
anterior descending artery disease with CABG receiving 1A support.1 For PCI the 
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level of recommendation in 2010 was IIa (conflicting evidence and/or divergence 
of opinion although the weight of evidence is in favour of its usefulness). The 
level of evidence supporting this recommendation was B (the data is derived from 
a single clinical trial or large non-randomised studies). In a similar fashion the 
2011 AHA/ACC CABG and 2012 AHA/ACC stable angina guidelines both state that 
CABG with a LIMA graft to improve survival is reasonable in patients with 
significant (>70% diameter) stenosis in the proximal LAD artery and evidence of 
extensive ischemia (recommendation IIa, level of evidence B).2 In contrast PCI is 
recommended at a level of IIb (uncertain benefit) but also with a B level of 
evidence. 
 
However the latest ESC/EACTS guidelines on myocardial revascularisation 
published this year recommended treatment of an isolated proximal left anterior 
descending artery (LAD) stenosis with either coronary artery bypass grafting 
(CABG) or percutaneous coronary intervention (PCI) in patients presenting with 
stable angina or non-ST elevation myocardial infarction.3 This revascularisation 
strategy was recommended irrespective of co-existing coronary disease, thus it 
applied to isolated proximal LAD disease only as well as to multi-vessel disease. 
Both revascularisation strategies received equal support with a Class 1 indication 
(that the evidence and/or general agreement is that the treatment is beneficial, 
useful and effective). Additionally the level of evidence supporting this 
recommendation was deemed to be A (the data were derived from multiple 
clinical trials). 
 
In a critical appraisal of the updated 2014 ESC/EACTS guidelines readers might 
expect that a major change to the proximal LAD revascularisation guidance would 
be supported by extensive new data since 2010. In fact the upgrade to for PCI 
from IIa/(B) - that there is conflicting evidence and/or divergence of opinion with 
the data is derived from a single clinical trial or large non-randomised studies - to 
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IA - that there is general agreement is that the treatment is beneficial, useful and 
effective with the data the data was derived from multiple clinical trials – is not 
supported by any referenced data in the guidelines. In fact none of the studies 
listed in Table 2 are included in the guideline references. Additionally there is no 
mention of the 2 recently published meta-analyses.30,31 Although 3 studies have 
reported between 2010 and 2014 ESC guidelines, in fact all three showed excess 
TLR with PCI vs. CABG (Etienne21 OR 5.88, Dohi28 OR 12.5 and Benedetto29 OR 
2.0) However as discussed above there is a paucity of data which does not 
appear firm enough to allow definitive conclusions to be drawn and might be 
interpreted as supporting the continuation of CABG as the preferred treatment. 
Thus the data that drive the upgrade of PCI for proximal LAD revascularisation in 
the guidelines are not clear from the available evidence base.  
 
Summary 
In summary although most interventional cardiologists would assert that a 2nd or 
3rd generation DES-PCI is the definitive treatment for isolated proximal LAD 
stenosis based on the low TLR rates of contemporary DES implantation, and 
reassuring data on left main stem intervention, there are few data available. Thus 
it remains scientifically unproven as to the optimal revascularisation strategy for 
isolated stenosis of the proximal LAD. To fill this data void (and paradoxically 
support the guidelines) a multi-centre randomised controlled trial with as 
complete and consecutive enrolment as practically feasible should be performed. 
However in order for this trial to be informative as possible (and to minimise 
selection bias) it should be an all-comers trial with as complete randomisation of 
eligible patients as possible. Whether or not interventional cardiologists would 
suppress their inherent biases about the best treatment and recruit to such a trial 
however remains to be seen. 
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